Search This Blog

Tuesday, August 19, 2025

The Creation of New ICD-10 Codes for Post-Covid Vaccine Syndrome

 Definitions matter. In almost any context, problems left undefined inevitably remain problems left unsolved.

For this reason, healthcare professionals worldwide rely upon the International Classification of Diseases, Tenth Revision (ICD-10), a standardized system used to categorize and code diseases, symptoms, and health conditions. In the United States, ICD-10 codes serve as the foundation for medical records, insurance billing, epidemiological research, and public health policy. Without specific ICD-10 codes, severe conditions may remain invisible in the healthcare data ecosystem—making it harder to track, study, or provide adequate care.

This is precisely the challenge facing thousands of Americans suffering from persistent severe adverse events after receiving a Covid vaccine—a condition recently defined as Post-Covid Vaccine Syndrome (PCVS). As one of those individuals, I know all too well how debilitating and life-altering this condition can be. Our symptoms include exercise intolerance, excessive fatigue, brain fog, insomnia, and dizziness. They develop shortly after vaccination, within a day or two, can become more severe in the days that follow, and persist over time.

At present, there are no dedicated ICD-10 codes for PCVS. This absence has significant consequences for patients, clinicians, researchers, and policymakers alike.

Visibility in the Healthcare System

One of the primary functions of ICD-10 codes is to make a condition visible within the healthcare system. Without specific codes, PCVS is at best recorded under vague categories like “unspecified adverse effect of vaccine” or “other specified postvaccination complication.” Leery of contradicting the safe and effective narrative, many providers simply utilize codes for general symptoms such as “fatigue” or “paresthesia.” As a result, PCVS is effectively lost in a sea of unrelated data.

Dedicated codes would allow providers to document PCVS in a standardized way, ensuring it is recognized in patient records, insurance claims, and national health databases. This visibility is crucial for legitimizing PCVS in the eyes of both a conflicted medical community and a polarized public.

Facilitating Research and Data Collection

Medical research thrives on accurate, reliable data. Without discrete ICD-10 codes, it is extremely difficult to track how many of us are affected by PCVS, what our symptoms are, how long they last, and what treatments are effective.

Currently, researchers who want to study PCVS must sift through miscellaneous adverse event codes, searching for possible cases—a process that is slow, imprecise, and prone to undercounting. Specific codes would enable more precise epidemiological studies, making it easier to identify risk factors, compare outcomes, and develop evidence-based treatment guidelines.

Improving Public Health Response and Policy

Public health agencies use ICD-10 coding data to monitor trends, allocate resources, and shape policy decisions. The lack of codes for PCVS means that policymakers are operating without a complete picture of vaccine safety profiles and long-term outcomes.

By establishing dedicated codes, health officials could more accurately assess the frequency and severity of PCVS, helping them balance the benefits and risks of vaccination programs and design better safety monitoring systems in the future. This transparency would strengthen public confidence in vaccination campaigns by demonstrating that potential adverse events are being taken seriously and tracked systematically.

Reducing Stigma and Improving Clinical Recognition

Those of us suffering from PCVS often face intense skepticism, with our symptoms crudely dismissed as unrelated or psychosomatic. The absence of recognized diagnostic codes can inadvertently reinforce this stigma, making it harder for those suffering with PCVS to be taken seriously.

Specific ICD-10 codes would send a clear signal to clinicians that PCVS is a legitimate medical condition worthy of investigation, empathy, and appropriate care.

Ethical and Societal Responsibility

Healthcare systems have an ethical duty to acknowledge and address all medical conditions – especially those that may be rare or controversial. Creating specific ICD-10 codes for PCVS would demonstrate a commitment to transparency, patient welfare, and scientific inquiry.

This step would not undermine legitimate vaccination efforts; rather, it would enhance them by showing the public that adverse events are being tracked rigorously and addressed proactively. Public health trust depends not only on promoting the benefits of a medical intervention but also on an honest acknowledgment of its risks, however small.

Aligning with the Approach to Long Covid

The World Health Organization and the US Centers for Disease Control and Prevention (CDC) have already recognized the need for specific ICD-10 codes for post-acute sequelae of Covid, commonly known as Long Covid. These codes have helped researchers and clinicians better identify, study, and manage that condition.

The same logic applies to PCVS. Both prolonged conditions involve complex overlapping symptoms following an acute event (infection or vaccination) and require long-term monitoring. 

For that reason, React19, a science-based 501(c) non-profit organization dedicated solely to supporting those suffering from long-term Covid vaccine adverse events, has submitted a formal proposal to the CDC’s National Center for Health Statistics to create ICD-10 codes for PCVS mirroring those for Long Covid. 

PCVS Patients Deserve Action, not Argument

While opinions differ greatly to what extent – by all credible accounts the Covid vaccines simply did not perform as public health officials assured the American public they would. As to efficacy, they failed to stop transmission and infection. As to safety, in addition to the emergence of PCVS, the CDC has conceded that myocarditis and pericarditis are “linked to certain types of COVID-19 vaccinations.” And of course, the Johnson & Johnson vaccine was pulled entirely from the market after multiple cases of fatal blood clotting after vaccinations. 

Yale Medical School professor of cardiology Dr. Harlan Krumholtz well summarized, “It’s clear that some individuals are experiencing significant challenges after vaccination. Our responsibility as scientists and clinicians is to listen to their experiences, rigorously investigate the underlying causes, and seek ways to help.” Creating distinct ICD-10 codes for PCVS mirroring those currently utilized to identify Long Covid would be the logical first step to provide this much needed support.

Failure to create specific ICD-10 codes for PCVS would be to ignore the agonizing reality of the syndrome, leaving the sick and suffering to face the grim consequences of inaction – left adrift in a medical system unwilling to acknowledge our existence and desperate need for treatment. We must expect more of our public health agencies – those debilitated by PCVS deserve no less. 

  • Prior to his own life altering vaccine injury, Chris primarily practiced criminal defense throughout central Pennsylvania. His client base ranged from individuals facing minor offenses such as driving under the influence to those charged with serious offenses including homicide. In addition to his private clients, Chris served as court-appointed counsel representing incarcerated individuals under Pennsylvania’s Post Conviction Relief Act. In 2009, he was recognized as Advocate of the Year for his work on behalf of victims of violent crime. He is now Legal Affairs Director of React19, a science-based non-profit offering financial, physical, and emotional support for those suffering from longterm Covid-19 vaccine adverse events globally.

  • https://brownstone.org/articles/the-creation-of-new-icd-10-codes-for-post-covid-vaccine-syndrome/

Medtronic Stock: Raised EPS Guidance Reflects Confidence in Market Expansion

 Medtronic (NYSE:MDT) plc has released its financial results for the first quarter of fiscal year 2026, showcasing a notable performance that exceeded market expectations. This article delves into the details of the current quarter’s performance and provides insights into the company’s future guidance.

Medtronic Plc Reports Strong First-Quarter FY’26 Results

Medtronic plc reported a robust first quarter for fiscal year 2026, ending July 25, 2025. The company achieved a revenue of $8.6 billion, surpassing the expected $8.37 billion. This marks an 8.4% increase as reported and a 4.8% rise on an organic basis. The company’s non-GAAP diluted earnings per share (EPS) reached $1.26, exceeding the anticipated $1.23, while the GAAP diluted EPS stood at $0.81, marking a 1% increase from the previous year.

Key drivers for this growth included significant gains in the Cardiac Ablation Solutions segment, which saw a nearly 50% increase, with a remarkable 72% growth in the U.S. market. The company’s Cardiovascular and Diabetes segments also contributed to the overall revenue increase, with 9.3% and 11.5% growth, respectively. Medtronic’s success was largely attributed to its innovative product lines, including Pulsed Field Ablation and Transcatheter Valves, which have consistently driven revenue.

Despite the positive performance, the company’s operating margin showed mixed results. The GAAP operating margin increased by 70 basis points to 16.8%, while the non-GAAP operating margin decreased by 80 basis points to 23.6%. These figures reflect the company’s strategic investments in research and development, sales, and marketing to support long-term growth objectives.

Medtronic Raises Full Year EPS Guidance for Fiscal 2026

Medtronic has raised its fiscal year 2026 EPS guidance, reflecting its confidence in continued growth. The company now anticipates diluted non-GAAP EPS growth of approximately 4.5%, up from the previous guidance of 4%. This adjustment accounts for a reduced potential impact from tariffs, which are expected to decrease from an earlier estimate of $200 million to $350 million, down to approximately $185 million.

The company maintains its forecast for organic revenue growth at about 5% for FY26. Including the effects of foreign currency exchange, Medtronic expects reported revenue growth to range between 6.5% and 6.8%. This outlook is supported by the company’s ongoing efforts to enhance efficiencies in manufacturing and supply chain operations, as well as its commitment to increasing investments in research and development.

Medtronic’s leadership expressed optimism about the company’s future prospects, highlighting the anticipated acceleration in revenue growth during the second half of the fiscal year. The company’s strategic focus on innovative product development and market expansion is expected to sustain its competitive edge in the healthcare technology sector.

https://www.investing.com/analysis/medtronic-stock-raised-eps-guidance-reflects-confidence-in-market-expansion-200665547

Judge rejects Elevance Health’s lawsuit over medicare advantage ratings

 Elevance Health loses $375M bonus revenue as court upholds CMS's Medicare Advantage rating methodology. 

https://seekingalpha.com/news/4487179-judge-rejects-elevance-healths-lawsuit-over-medicare-advantage-ratings

Novartis taps Atropos AI for earlier PNH diagnoses

 Novartis has joined forces with real-world evidence (RWE) specialist Atropos Health, hoping to improve the diagnosis of people with rare disease paroxysmal nocturnal haemoglobinuria (PNH) through the use of AI.

Under the terms of the collaboration, Atropos will "build, train, and evaluate" multiple models that they hope will speed up PNH diagnoses and the onset of treatment for the disorder, in which the body's complement system destroys red blood cells, leading to anaemia and fatigue and, in some cases, the need for regular blood transfusions.

Novartis is in the commercial rollout phase for an oral PNH treatment, targeted Factor B inhibitor Fabhalta (iptacopan), which is growing fast as an alternative to injectable or intravenous treatments like AstraZeneca's complement C5 inhibitors Soliris (eculizumab) and Ultomiris (ravulizumab), Apellis' C3 inhibitor Aspaveli (pegcetacoplan), and Roche's C5 inhibitor PiaSky (crovalimab).

Adults with PNH often experience lengthy delays before they get a diagnosis – sometimes as long as five years – because the disease is rare and causes variable symptoms across multiple organ systems.

Accelerating diagnosis using AI could reduce the time from symptom reporting to testing, diagnosis and treatment, and potentially help Novartis build towards its lofty peak sales hopes for Fabhalta – currently modelled at around $3 billion a year. The company has suggested that having an oral treatment option can "reset the expectations" of people living with PNH.

According to Palo Alto, California-based Atropos, its researchers have already come up with an initial AI model that has shown promise in detecting PBH earlier by analysing symptoms such as anaemia, age, haemoglobin, creatinine, and haptoglobin counts, and diagnostic and medication history.

"Building AI models tested and trained on high-quality real-world data is truly the next frontier in precision medicine," said Dr Brigham Hyde, Atropos' chief executive and co-founder.

"The accuracy of the models reduces the guesswork, and patients who are able to get testing sooner provides a potentially life-changing experience," he added. "For providers and health systems, faster time to diagnosis and treatment equate to higher patient satisfaction."

It is estimated that approximately 10-20 people per million worldwide live with PNH. It can develop at any age, though it is often diagnosed in people between 30-40 years old. Despite treatment with complement inhibitors, a large proportion of patients can remain anaemic and dependent on blood transfusions.

https://pharmaphorum.com/news/novartis-taps-atropos-ai-earlier-pnh-diagnoses

FDA Rejects PTC Therapeutics’ Friedreich’s Ataxia Drug

 

The small molecule, vatiquinone, had already flunked a Phase III trial, but the company pushed ahead with an approval bid anyway.

The FDA has rejected PTC Therapeutics’ vatiquinone, the company’s proposed treatment for Friedreich’s ataxia in children and adults.

In its complete response letter, the FDA stated that “substantial evidence of efficacy was not demonstrated” and that PTC would need an additional “adequate and well-controlled study” to support a resubmission, the company revealed in its press release Tuesday morning.

Shares of PTC are up about 6% in Tuesday morning trading.

Matthew Klein, the company’s CEO, said in a statement that PTC is planning to meet with the FDA to discuss potential next steps.

Friedreich’s ataxia is a rare neuromuscular disorder, stemming from a mutation in the frataxin gene that leads to mitochondrial dysfunction and cell death. Symptoms include loss of coordination and muscle strength, as well as difficulty speaking, swallowing and breathing. According to PTC, about 25,000 people have Friedreich’s ataxia globally.

Vataquinone is a small molecule that blocks some of the cellular pathways that go awry in patients with frataxin mutations. The drug had previously missed the mark in a Phase III, registration-directed trial back in 2023, failing to meet its primary endpoint of improving gait, stability and limb function after 72 weeks. Nevertheless, based on meeting some secondary endpoints like improving stability, PTC went ahead and sought registration with the FDA.

The only drug on the market for Friedreich’s ataxia is Skyclarys, approved in early 2023 when it was held by Reata Pharmaceuticals. Skyclarys, also a small molecule therapy, works by activating other cellular pathways to reduce the inflammation that Friedreich’s ataxia can cause. Following the drug’s approval, Biogen acquired Reata for about $7.3 billion.

PTC is the latest biotech to receive an FDA rejection in the rare disease space in recent weeks. Last month, Capricor Therapeutics was hit with a surprise CRL for its Duchenne muscular dystrophy asset deramiocel, while Ultragenyx’s UX111for Sanfilippo syndrome type A also got turned away unexpectedly by the agency.

https://www.biospace.com/fda/fda-rejects-ptc-therapeutics-friedreichs-ataxia-drug

Trump Addresses Backfiring Green Policies Sparking Mid-Atlantic Power Bill Crisis

 President Trump weighed in on the Mid-Atlantic power crisis on Truth Social early Tuesday, echoing our warnings last week about the fallout from Democrats' multi-year "green" crusade to replace reliable, low-cost fossil fuel power plants with unreliable solar and wind amid power demand surges from AI data centers and other electrification trends. The result has been financially crushing for some residents across the Mid-Atlantic. In Maryland, Democrats' approval ratings are already tanking.

"STUPID AND UGLY WINDMILLS ARE KILLING NEW JERSEY," President Trump wrote on Truth Social moments ago. 

He continued, "Energy prices up 28% this year, and not enough electricity to take care of state. STOP THE WINDMILLS!"

Trump's use of Truth Social to address the unfolding power bill crisis in the Mid-Atlantic comes after our year-long reporting (read) on the emerging crisis, which has been amplified nationally in recent weeks...

The Trump administration needs to address the power bill crisis by showing voters in both states that a common denominator of destructive policies is driving the crisis: A disastrous green energy agenda, pushed by radical leftist lawmakers, is dismantling reliable and affordable fossil fuel power generation in favor of unstable solar and wind. This has unleashed a power bill armageddon on working-class and middle-class households, as well as mom-and-pop businesses, all while baseload power demand surges in the era of AI data centers.

Fox News jumped on the power bill crisis story last week...

Perhaps New Jersey Gov. Phil Murphy's decision to shutter the state's nuclear and coal plants, without a one-to-one replacement for lost capacity on the grid, was a catastrophic error. His administration's prioritization of offshore wind farms and other green energy projects has left the grid more fragile than ever. 

In Maryland, the power bill crisis seems much more severe than in New Jersey!

Failed green policies are crushing the very working poor and middle class that Democrats have promised to protect. Yet the green utopia that was pitched was always a lie.  

According to Change Annapolis, a bipartisan group of taxpayers, Maryland Gov. Wes Moore's ratings plunged over a multitude of issues, including power bills: "Marylanders are tired of his presidential vanity tour, crushing tax hikes, and an energy crisis of his own making," adding, "He's polling worse than O'Malley and Glendening at this point in their terms."

The power bill crisis is still in its early stages. Goldman analyst Hongcen Wei wrote an alarming note to clients last week, warning that a majority of U.S. power grids "have already reached dangerously low spare capacity levels that are at or below the critical reliability threshold. This raises blackout threats and results in power price spikes during high-demand usage hours."

In other words, the power crisis has arrived, and it's only going to get worse from here. The Trump administration needs to effectively communicate to voters that skyrocketing power bills are the direct result of failed green policies in the age of AI data centers.

We've got bad news... read this

https://www.zerohedge.com/ai/president-trump-addresses-backfiring-green-policies-sparking-mid-atlantic-power-bill-crisis

VViking crashes after weight-loss pill trial shows high dropout rate

 Viking Therapeutics (VKTX) stock crashed more than 40% in early trading on Tuesday after a phase 2 trial of its weight-loss pill showed a high patient dropout rate.

The company stated that most of the adverse treatment-related symptoms were gastrointestinal in nature, and 99% of the adverse events were mild. Over half (58%) of participants taking the drug reported nausea, compared with 48% for placebo, and a quarter of patients reported vomiting.

The obesity treatment showed some promising results: After 13 weeks of once-daily dosing, patients lost 12.2% of their body weight (26.6 lbs on average), compared with a 1.3% loss (2.9 lbs) for the placebo. However, 28% of patients discontinued the treatment before the trial was completed.

Viking's oral obesity drug, VK2735, aims to compete with Eli Lilly's drug, orforglipron, which revealed results from its phase 3 trials earlier this month.

Eli Lilly's results earlier this month showed patients taking its treatment had a weight-loss rate of 12.4% (27.3 lbs) after 72 weeks. Analysts similarly noted that Eli Lilly's pill had a high patient dropout rate — 25% at the highest dose — and the stock dropped 14% in one day following the results.

However, Viking Therapeutic's update may be casting a new light on Eli Lilly's late-stage trials as the race to develop a weight-loss pill heats up.

"Data look inferior to LLY on almost all metrics and the thing to consider here is that patients discontinued at such a high rate over 13-weeks vs. LLY in the mid 20% range — but over 72-weeks," Mizuho analyst Jared Holz wrote in a note. "A much longer trial, and [therefore] LLY looks far better head-to-head."

Following the results, Eli Lilly stock (LLY) rose 1.7% on Tuesday, while Novo Nordisk (NVO) also rose more than 1%.

https://finance.yahoo.com/news/viking-therapeutics-stock-crashes-after-weight-loss-pill-trial-shows-high-dropout-rate-145717807.html